2. Academic Validation
  3. Mutations in the Neuronal Vesicular SNARE VAMP2 Affect Synaptic Membrane Fusion and Impair Human Neurodevelopment

Mutations in the Neuronal Vesicular SNARE VAMP2 Affect Synaptic Membrane Fusion and Impair Human Neurodevelopment

  • Am J Hum Genet. 2019 Apr 4;104(4):721-730. doi: 10.1016/j.ajhg.2019.02.016.
Vincenzo Salpietro 1,  Nancy T Malintan 2,  Isabel Llano-Rivas 3,  Christine G Spaeth 4,  Stephanie Efthymiou 5,  Pasquale Striano 6,  Jana Vandrovcova 7,  Maria C Cutrupi 8,  Roberto Chimenz 8,  Emanuele David 9,  Gabriella Di Rosa 10,  Anna Marce-Grau 11,  Miquel Raspall-Chaure 11,  Elena Martin-Hernandez 12,  Federico Zara 13,  Carlo Minetti 6,  Deciphering Developmental Disorders Study,  SYNAPS Study Group,  Oscar D Bello 2,  Rita De Zorzi 14,  Sara Fortuna 15,  Andrew Dauber 16,  Mariam Alkhawaja 17,  Tipu Sultan 18,  Kshitij Mankad 19,  Antonio Vitobello 20,  Quentin Thomas 21,  Frederic Tran Mau-Them 20,  Laurence Faivre 22,  Francisco Martinez-Azorin 23,  Carlos E Prada 4,  Alfons Macaya 11,  Dimitri M Kullmann 2,  James E Rothman 24,  Shyam S Krishnakumar 25,  Henry Houlden 26
Affiliations

Affiliations

  • 1 Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa 16147, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa 16132, Italy; Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London WC1N 3BG, UK.
  • 2 Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, London WC1N 3BG, UK.
  • 3 Department of Medical Genetics, Hospital Universitario Cruces, Greater Bilbao 48903, Spain.
  • 4 Division of Human Genetics, Department of Pediatrics, University of Cincinnati, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3026, USA.
  • 5 Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London WC1N 3BG, UK; Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, London WC1N 3BG, UK.
  • 6 Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa 16147, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa 16132, Italy.
  • 7 Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London WC1N 3BG, UK.
  • 8 Division of Human Genetics, Department of the Adult and Developmental Age Human Pathology, University of Messina, Messina 98125, Italy.
  • 9 Papardo University Hospital, Viale Ferdinando Stagno d'Alcontres, Contrada Papardo, Messina 98158, Italy.
  • 10 Division of Child Neurology and Psychiatry, Department of the Adult and Developmental Age Human Pathology, University of Messina, Messina 98125, Italy.
  • 11 Department of Pediatric Neurology, University Hospital Vall d'Hebron, Barcelona 08035, Spain.
  • 12 Unidad de Enfermedades Mitocondriales-Metabólicas Hereditarias, Departamento de Pediatría, Hospital 12 de Octubre, Madrid 28041, Spain.
  • 13 Laboratory of Neurogenetics and Neuroscience, G. Gaslini Institute, Genova 16147, Italy.
  • 14 Center of Excellence in Biocrystallography, Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste 34127, Italy.
  • 15 Department of Chemical and Pharmaceutical Sciences, University of Trieste, Trieste 34127, Italy.
  • 16 Division of Endocrinology, Cincinnati Center for Growth Disorders, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3026, USA.
  • 17 Prince Hamzah Hospital, Ministry of Health, Amman 11181, Jordan.
  • 18 Department of Pediatric Neurology, Institute of Child Health and The Children's Hospital Lahore, 381-D/2, Lahore 54600, Pakistan.
  • 19 Department of Neuroradiology, Great Ormond Street Hospital for Children, London WC1N 3JH, UK.
  • 20 Unité Fonctionnelle Innovation en Diagnostic Genomique des Maladies Rares, Center Hospitalier Universitaire Dijon Bourgogne, Dijon 21079, France; Inserm, UMR 1231, Genetique des Anomalies du Development, Université de Bourgogne, Dijon 21079, France.
  • 21 Inserm, UMR 1231, Genetique des Anomalies du Development, Université de Bourgogne, Dijon 21079, France.
  • 22 Inserm, UMR 1231, Genetique des Anomalies du Development, Université de Bourgogne, Dijon 21079, France; Center de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital d'Enfants, Dijon 21079, France.
  • 23 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid 28041, Spain.
  • 24 Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, London WC1N 3BG, UK; Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520, USA.
  • 25 Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, University College London, London WC1N 3BG, UK; Department of Cell Biology, Yale University School of Medicine, New Haven, CT 06520, USA. Electronic address: s.krishnakumar@ucl.ac.uk.
  • 26 Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, London WC1N 3BG, UK. Electronic address: h.houlden@ucl.ac.uk.
PMID: 30929742 DOI: 10.1016/j.ajhg.2019.02.016
Abstract

VAMP2 encodes the vesicular SNARE protein VAMP2 (also called synaptobrevin-2). Together with its partners syntaxin-1A and synaptosomal-associated protein 25 (SNAP25), VAMP2 mediates fusion of synaptic vesicles to release neurotransmitters. VAMP2 is essential for vesicular exocytosis and activity-dependent neurotransmitter release. Here, we report five heterozygous de novo mutations in VAMP2 in unrelated individuals presenting with a neurodevelopmental disorder characterized by axial hypotonia (which had been present since birth), intellectual disability, and autistic features. In total, we identified two single-amino-acid deletions and three non-synonymous variants affecting conserved residues within the C terminus of the VAMP2 SNARE motif. Affected individuals carrying de novo non-synonymous variants involving the C-terminal region presented a more severe phenotype with additional neurological features, including central visual impairment, hyperkinetic movement disorder, and epilepsy or electroencephalography abnormalities. Reconstituted fusion involving a lipid-mixing assay indicated impairment in vesicle fusion as one of the possible associated disease mechanisms. The genetic synaptopathy caused by VAMP2 de novo mutations highlights the key roles of this gene in human brain development and function.

Keywords

SNARE; VAMP2; autism; epilepsy; movement disorders; neurodevelopmental disorders; neuronal exocytosis; synaptobrevin; synaptopathy; vesicle fusion.

Figures